FDA Removes Clinical Hold On Celyad’s Colorectal Cancer Trial
The FDA has lifted the clinical hold on Celyad Oncology SA’s (NASDAQ:CYAD) CYAD-101-002 (KEYNOTE-B79) Phase 1b trial after the company made changes…
Celyad Oncology Announced FDA Lifted Clinical Hold of CYAD-101-002 Phase 1b Trial
Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ: CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the U.S.
Eledon Pharmaceuticals Received FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that the U.S.
Biotech Investors: August’s Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the month were new molecular entities, underlining a lack of innovation going on in the sector.
Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August
The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ: ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older.
FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced today that the U.S. Food and Drug
Duchenne Gene Therapy Firm Sarepta Therapeutics’ Earns 8% Price Target Hike From This Analyst
Earlier today, Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that it would submit the marketing application and seek accelerated FDA approval for SRP-9001 in…